Clinical Trial Update: Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease [Phase 1]

View source ↗

Summary

This Phase 1 clinical trial evaluated abatacept as prophylaxis against graft-versus-host disease after hematopoietic stem cell transplantation in pediatric sick…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease
• Sickle Cell Disease

Drugs mentioned

• ORENCIA (ABATACEPT)

Snippet

Sponsor: Monica Bhatia | Conditions: Sickle Cell Disease, Graft Versus Host Disease | Phase 1 | Status: COMPLETED